Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iberdomide + cyclophosphamide + dexamethasone
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Iberdomide + cyclophosphamide + dexamethasone is an investigational, fully oral combination therapy being studied primarily for relapsed or refractory multiple myeloma (RRMM). Iberdomide is a novel cereblon E3 ligase modulator (CELMoD) that binds with high affinity to cereblon, leading to enhanced degradation of transcription factors Ikaros and Aiolos. This results in direct anti-myeloma activity and immune-stimulatory effects, including increased activation of T cells and natural killer (NK) cells. Cyclophosphamide is an alkylating chemotherapy agent with immunomodulatory properties that can potentiate the effects of immunomodulatory drugs. Dexamethasone is a corticosteroid used to reduce inflammation and suppress immune responses, commonly included in myeloma regimens to mitigate side effects and enhance efficacy. The combination has shown promising clinical activity in patients who have received multiple prior lines of therapy[2][6][7][8].
- Other names
- IberCd
02
Targets
CRBN (Cereblon)DNAGR (Glucocorticoid receptor)
Beyond the preview
Go deeper on iberdomide + cyclophosphamide + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iberdomide + cyclophosphamide + dexamethasone.